4M Therapeutics to Present at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

SKILLMAN, N.J. -- 4M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced that the Company’s CEO, Pablo Lapuerta, M.D., will present a poster at the upcoming American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting taking place May 26-29 2026, in Miami, FL.

Details of the poster presentation are below:

ASCP 2026 Annual Meeting

• Title: Preclinical Efficacy of Concomitant Administration of Novel GSK3β Inhibitor 4MT-A and Lithium Orotate

• Session Date and Time: Wednesday, May 27, 2026 at 11:45 a.m. ET

About 4M Therapeutics Inc.

4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative conditions. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaboration between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics. The Company’s pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net.

Contacts

For investor and media inquiries, please contact:
Kimberly Lee, DO
Chief Business Officer
ir@4mtx.net